Amylyx Pharmaceuticals has appointed Jeffrey Trigilio to serve as its first chief financial officer. Trigilio was most recently vice president of finance at cell therapy company BlueRock Therapeutics. His previous experience includes time at Alexion Pharmaceuticals (NASDAQ: [[ticker:ALXN]]).
Amylyx, which is based in Cambridge, MA, is developing new treatments for amyotrophic lateral sclerosis (ALS), Alzheimer’s disease, and other neurodegenerative diseases. The biotech has two programs in Phase 2.
Author: Sarah de Crescenzo
Sarah is Xconomy's San Diego-based editor. Prior to joining the team in 2018, she wrote about startups, tech and finance at the San Diego Business Journal. Her decade of full-time news experience includes coverage of subjects including campaign finance, crime and courts as a reporter and editor at outlets throughout California, including the Orange County Register.
She earned a bachelor's degree in English Literature at UC San Diego, where she wrote for the student newspaper and played collegiate lacrosse. In 2019, she earned an MBA at UC Irvine.
View all posts by Sarah de Crescenzo
